Navigation Links
ACS Announces $57 Million Contract With Missouri HealthNet
Date:3/7/2008

DALLAS, March 7 /PRNewswire-FirstCall/ -- Affiliated Computer Services, Inc. (NYSE: ACS) today announced a contract renewal with the Missouri (MO) HealthNet Division to provide electronic health records and pharmacy benefits management solutions. The contract has a length of up to 10 years and a total value of $57 million if all option years are exercised.

Under this contract, ACS will provide the state with several components of ACS' electronic health records (EHR) solution, including SmartPA(SM) for conducting automated prior authorizations and Prospective Drug Utilization Review. Since 2002, SmartPA has helped contribute more than $85 million in program savings annually in Missouri.

ACS has also provided MO HealthNet with Retrospective Drug Utilization review and academic detailing programs that have enabled the state to save more than $10 million. In 2002, ACS introduced the Get Well program, a disease management program, which helped the state save more than $7 million.

"We have worked closely with the State of Missouri to help them achieve their vision of providing MO HealthNet participants with the best care possible through innovative clinical and technology solutions," said Christopher T. Deelsnyder, ACS senior vice president and managing director, Government Healthcare Solutions. "ACS is noted for listening to our customers, learning about their business requirements, and implementing solutions for participants, providers, and taxpayers in each of the states we serve."

This contract renewal was reflected in the second quarter fiscal year 2008 results and extends a relationship that began in 2001.

ACS will also deploy EHR web tools -- DirectInform(SM), CyberAccess(SM) and DirectCarePro(SM) -- tha
'/>"/>

SOURCE Affiliated Computer Services, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Nfocus Neuromedical Announces Acquisition of StarFire Medical
2. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Cancer Indexes
3. Pharos Innovations Announces First Recipient of National Award for Achievements in Chronic Care Programs and Research
4. Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
5. The Hain Celestial Group Announces the Acquisition of MaraNatha(R) and SunSpire(R) Brands
6. Cardiogenesis Corporation Announces Rescheduled Fourth Quarter and Full Year 2007 Earnings Release
7. Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming SAWC Conference
8. Milestone Scientific Announces Chicago Dental Societys 143rd Midwinter Meeting Proved Successful
9. Zounds Hearing Enters Moorestown and Announces $225,000 Hearing Partnership With Twilight Wish Foundation
10. Pregis Announces Investor Conference Call to Review 2007 Fourth Quarter and Full Year Financial Results
11. Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 2Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 3ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 1ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 2ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 3Provocative New Fiction Makes for a Fascinating Fast Paced Read 13713 1Provocative New Fiction Makes for a Fascinating Fast Paced Read 13713 2LiveProcess Implements Emergency Management Platform with 51 Florida Hospitals 55482 1LiveProcess Implements Emergency Management Platform with 51 Florida Hospitals 55482 2